Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Varex Imaging Corporation (VREX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded Nasdaq issuer. Varex designs and manufactures X-ray imaging components and systems for medical, industrial, and security applications, and its filings offer detailed insight into how this business is reflected in its financial statements, risk factors, and governance disclosures.
Through this page, users can review Varex’s periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which present segment information for the Medical and Industrial businesses, revenue composition, gross margin, operating expenses including research and development, and details on capital structure items like long-term debt and convertible notes. These filings also contain management’s discussion and analysis and other disclosures that complement the high-level figures in press releases.
Current reports on Form 8-K document specific material events. For example, a recent 8-K furnished an earnings press release titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” while another 8-K described a transition agreement with the company’s Senior Vice President, Chief Legal Officer, and Corporate Secretary, outlining continued service, compensation, and equity vesting terms. Such filings help investors track both financial performance and key governance changes.
On Stock Titan, VREX filings are updated as they are made available through EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly understand topics such as segment performance, non-GAAP reconciliations, debt and liquidity, and executive arrangements. Users can also review ownership and insider activity through forms that report transactions by officers and directors, providing an additional perspective on Varex Imaging Corporation’s regulatory record.
Varex Imaging Corp executive Jesse Don Merkley, SVP and GM, Industrial, filed an initial ownership report showing his equity stake in the company. He directly holds 15,334 shares of common stock as of the reported date.
He also holds several equity awards, including restricted stock units and performance stock units that each convert into common stock on a one-for-one basis as vesting and performance conditions are met. In addition, he holds a non-qualified stock option covering 9,727 shares of common stock at an exercise price of $24.55 per share, expiring in 2033, along with multiple RSU and PSU grants that vest over time and are tied to fiscal-year performance criteria.
Varex Imaging Corp ownership disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting 0 shares beneficially owned of Varex Imaging Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 that prompted disaggregated reporting by Vanguard subsidiaries. The amendment is signed by Ashley Grim on 03/27/2026.
Varex Imaging Corp senior vice president of regulatory and quality assurance Victor Hugo Garcia filed a Form 3 detailing his existing equity stake in the company. The filing shows direct ownership of 23,360 shares of common stock, along with multiple blocks of restricted stock units, performance stock units, and non-qualified stock options. These derivative awards cover underlying common shares at exercise prices ranging from $22.13 to $31.42, with option expirations extending through December 8, 2032. The entries reflect current holdings rather than new open‑market purchases or sales.
Varex Imaging Corp director Jay K. Kunkel sold shares in a routine open-market transaction. He sold 4,510 shares of common stock at a price of $11.14 per share. After this sale, he directly holds 23,450 shares, so he continues to maintain a significant equity stake in the company.
VREX submitted a Rule 144 notice relating to the sale of Common stock through Fidelity Brokerage Services LLC. The filing lists two previously vested restricted-stock items: 875 shares vested on 02/13/2023 and 3,635 shares vested on 02/11/2024900 Salem Street, Smithfield, RI and the exchange is shown as NASDAQ.
Varex Imaging Corporation has refinanced its debt by entering into a new Credit and Guaranty Agreement providing a $350 million secured term loan, a $100 million secured revolving credit facility, and a $40 million secured delayed draw term loan, for total commitments of $490 million maturing on March 13, 2031.
The company drew $350 million from the term loan and, together with about $42 million of cash, funded the redemption of $368 million of 7.875% Senior Secured Notes due 2027 and related costs. This reduced outstanding debt by $18 million and is expected to lower annual cash interest expense by more than $7 million.
Borrowings bear SOFR-based variable interest plus a margin tied to Varex’s consolidated net leverage ratio, with an interest rate swap fixing the SOFR component at 3.65% and an initial 2.50% margin. The prior $155 million revolving credit facility was terminated, and the new revolver supports working capital and general corporate purposes.
Varex Imaging Corporation reported the results of its 2026 annual meeting of stockholders. Stockholders representing 38,575,226 shares, about 92% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a strong quorum.
All seven director nominees — Kathleen L. Bardwell, Jocelyn D. Chertoff, Timothy E. Guertin, Jay K. Kunkel, Walter M. Rosebrough, Jr., Sunny S. Sanyal and Christine A. Tsingos — were elected to serve until the 2027 annual meeting of stockholders.
Stockholders also approved on an advisory basis the compensation of the company’s named executive officers and ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
Varex Imaging Corp director Kathleen Bardwell reported an acquisition of deferred stock units. On 02/12/2026, she received 12,331 Deferred Stock Units at a price of $0 per unit, all held as direct beneficial ownership.
Each Deferred Stock Unit converts into one share of common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting after the grant date. Vested shares will be delivered upon the earlier of the third anniversary of the grant date, a change in control, or the end of Bardwell’s service for any reason.
Varex Imaging Corp director Jay K. Kunkel received a grant of 12,331 Deferred Stock Units on February 12, 2026. The grant is recorded at a price of $0 per unit and is reported as directly owned.
Each Deferred Stock Unit converts into one share of Varex common stock. The units vest 100% on the earlier of one year from the grant date or the next annual stockholder meeting after the grant. Vested shares are delivered on the earlier of the third anniversary of the grant, a change in control, or Kunkel’s termination of service for any reason.
Varex Imaging Corp director Walter M. Rosebrough Jr. received a grant of 14,947 Deferred Stock Units on February 12, 2026. These units were awarded at a price of $0 as a form of equity compensation and are held as a derivative security.
Each Deferred Stock Unit converts into one share of Varex Imaging common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, and the underlying shares will be delivered on the earlier of the third anniversary of the grant, a change in control, or the director’s termination of service.